- Home
- UHG vs VNDA Comparison
UHG vs VNDA Comparison
Compare UHG & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UHG
- VNDA
- Stock Information
- Founded
- UHG 2004
- VNDA 2002
- Country
- UHG United States
- VNDA United States
- Employees
- UHG 175
- VNDA N/A
- Industry
- UHG Homebuilding
- VNDA Biotechnology: Pharmaceutical Preparations
- Sector
- UHG Consumer Discretionary
- VNDA Health Care
- Exchange
- UHG Nasdaq
- VNDA Nasdaq
- Market Cap
- UHG 158.8M
- VNDA 261.7M
- IPO Year
- UHG N/A
- VNDA 2006
- Fundamental
- Price
- UHG $2.87
- VNDA $4.91
- Analyst Decision
- UHG
- VNDA Strong Buy
- Analyst Count
- UHG 0
- VNDA 3
- Target Price
- UHG N/A
- VNDA $15.33
- AVG Volume (30 Days)
- UHG 215.6K
- VNDA 388.0K
- Earning Date
- UHG 08-07-2025
- VNDA 07-30-2025
- Dividend Yield
- UHG N/A
- VNDA N/A
- EPS Growth
- UHG N/A
- VNDA N/A
- EPS
- UHG 0.76
- VNDA N/A
- Revenue
- UHG $449,877,017.00
- VNDA $201,351,000.00
- Revenue This Year
- UHG N/A
- VNDA $16.86
- Revenue Next Year
- UHG N/A
- VNDA $39.78
- P/E Ratio
- UHG $3.74
- VNDA N/A
- Revenue Growth
- UHG 5.24
- VNDA 13.37
- 52 Week Low
- UHG $1.60
- VNDA $3.81
- 52 Week High
- UHG $6.93
- VNDA $6.37
- Technical
- Relative Strength Index (RSI)
- UHG 46.69
- VNDA 62.83
- Support Level
- UHG $2.62
- VNDA $4.85
- Resistance Level
- UHG $2.95
- VNDA $5.07
- Average True Range (ATR)
- UHG 0.32
- VNDA 0.16
- MACD
- UHG -0.10
- VNDA 0.02
- Stochastic Oscillator
- UHG 19.08
- VNDA 76.81
About UHG United Homes Group Inc
United Homes Group Inc operates as a homebuilder which operates with a land-light idea in the Southeast. The company currently has a presence in South Carolina, North Carolina, and Georgia and focuses on providing high-quality, affordable homes for the entry-level and first-move-up segments. The company has three reportable segments: GSH South Carolina, Rosewood, and Other.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.